

SUPPLEMENTARY TABLE 3. COVID-19 vaccination coverage* among persons aged ≥16 years, by Vaccine Type — Vaccine Safety Datalink (VSD), United States, December 14, 2020–May 15, 2021

Age Group (No.)	Vaccine Type, [†] No. (%)			
	All Vaccine Types	Moderna	Pfizer-BioNTech	J&J/Janssen
All Age Groups (≥16) (9,568,149)	4,624,351 (48.3)	2,065,088 (21.6)	2,352,592 (24.6)	206,671 (2.2)
16–17 (280,213)	82,976 (29.6)	0 (–)	82,976 (29.6)	0 (–)
18–24 (1,010,815)	289,898 (28.7)	122,331 (12.1)	154,419 (15.3)	13,148 (1.3)
25–34 (1,677,206)	604,382 (36.0)	257,642 (15.4)	318,756 (19.0)	27,984 (1.7)
35–49 (2,413,431)	1,056,291 (43.8)	455,502 (18.9)	548,308 (22.7)	52,481 (2.2)
50–64 (2,325,211)	1,264,761 (54.4)	582,030 (25.0)	602,151 (25.9)	80,580 (3.5)
65–74 (1,135,965)	771,078 (67.9)	379,987 (33.5)	369,309 (32.5)	21,782 (1.9)
≥75 (725,308)	554,965 (76.5)	267,596 (36.9)	276,673 (38.1)	10,696 (1.5)

Abbreviations: J&J/Janssen = Johnson & Johnson’s Janssen.

*Coverage is defined as first-dose of COVID-19 vaccine either as the first of two doses of the Pfizer-BioNTech or Moderna vaccines, or one dose of the Janssen (Johnson & Johnson) vaccine from December 14, 2020 through May 15, 2021.

[†]FDA issued Emergency Use Authorizations for use of the Pfizer-BioNTech COVID-19 vaccine on December 11, 2020, for use of Moderna COVID-19 vaccine on December 18, 2020, and for use of Johnson & Johnson’s Janssen (J&J/Janssen) COVID-19 vaccine on February 27, 2021